Get started
Author

AM Bode

P3-10-01: Alternative Dosing Regimens with the EGFr Inhibitors (Gefitinib and Lapatinib) in Mammary Cancer Models: Prevention and Therapeutic Efficacy.
2011 · RA Lubet, AM Bode, et al. · Cancer Research · 2
Abstract P1-08-03: Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor
2017 · C Guo, MJ Kuffel, et al. · Cancer Research · 1
Abstract P5-09-08: A comparison of the non-genomic effects of endoxifen and tamoxifen in aromatase inhibitor resistant breast cancer: Differential effects on the estrogen receptor co-regulator SRC3 (AIB1) and identification of PKC and PI3K as endoxifen substrates
2013 · MP Goetz, M Kuffel, et al. · Cancer Research · 1
P5-06-11: Quercetin-3-Methyl Ether Inhibits Lapatinib-Sensitive and Lapatinib-Resistant Breast Cancer Cell Growth by Inducing G2/M Arrest and Apoptosis.
2011 · AM Bode, J Li, et al. · Cancer Research
P3-11-07: Mammary Gland Biopsy To Examine Surrogate Endpoint Biomarkers of Preventive Agent Efficacy.
2011 · B Heckman-Stoddard, RA Lubet, et al. · Cancer Research
Abstract PD03-07: Evaluation of the Anti-Diabetic Drug Metformin in the Methylnitrosourea (MNU)-Induced Model of ER+ Mammary Cancer and the MMTV-Neu/p53KO Model of ER-Mammary Cancer
2010 · CJ Grubbs, AM Bode, et al. · Cancer Research
Abstract P2-07-03: Tumors Resistant to Iressa Treatment Show Increased Aberrant Expression of CREB (Ser133)
2010 · AM Bode, J Li, et al. · Cancer Research
Works count: 7
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type